SCHEMBL3920045

SCHEMBL3920045

O=C(O)c1cc(S(=O)O)ccc1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.57
TP53 P04637 1/20 0.57
TDP1 Q9NUW8 3/20 0.49
POLB P06746 3/20 0.49
KDM4E B2RXH2 2/20 0.49
NPC1 O15118 1/20 0.49
MAPT P10636 1/20 0.49
RAB9A P51151 1/20 0.49
LMNA P02545 1/20 0.47
CTSB P07858 1/20 0.45
TSHR P16473 4/20 0.42
CASP1 P29466 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
GRIK1 P39086 1/20 0.41
GRIA1 P42261 1/20 0.41
GRIA2 P42262 1/20 0.41
GRIA3 P42263 1/20 0.41
GRIA4 P48058 1/20 0.41
GRIK2 Q13002 1/20 0.41
GRIK3 Q13003 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4424022 0.78 CA1 (0.55) ALDH1A1TDP1KDM4ECTSBCASP1
SCHEMBL11228437 0.77 HSD17B10 (0.42) ALDH1A1TP53TDP1TSHRKMT2A
SCHEMBL10261850 0.77 MCL1 (0.40) ALDH1A1POLBKDM4ELMNATSHR
SCHEMBL3873276 0.77 CYP3A4 (0.40) ALDH1A1TP53KDM4ELMNATSHR
SCHEMBL19743221 0.74 MEN1 (0.36) ALDH1A1MAPTKMT2AMEN1
SCHEMBL2771204 0.73 ALDH1A1 (0.68) ALDH1A1TP53TDP1POLBKDM4E
SCHEMBL224469 0.73 ALDH1A1 (1.00) ALDH1A1TP53TDP1POLBKDM4E
SCHEMBL18746076 0.72 CA12 (0.48) ALDH1A1TP53KDM4ENPC1MAPT
SCHEMBL25891609 0.72 MCL1 (0.40) ALDH1A1NPC1RAB9ALMNATSHR
Hydrochloric Acid SCHEMBL699002 0.71 ALDH1A1 (0.95) ALDH1A1TP53TDP1POLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1874777-B 1-(2-amino-benzoyl)-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses HOFFMANN LA ROCHE 2012-07-04 CN disclosed
CN-101111477-B Benzoyl-tetrahydropyridine as glyt-1 inhibitors HOFFMANN LA ROCHE 2010-05-26 CN disclosed
US-7595314-B2 Benzoyl-piperazine derivatives HOFFMANN-LA ROCHE INC. (US) 2009-09-29 US disclosed
US-7595314-B2 Benzoyl-piperazine derivatives HOFFMANN-LA ROCHE INC. (US) 2009-09-29 US disclosed
US-7595314-B2 Benzoyl-piperazine derivatives HOFFMANN-LA ROCHE INC. (US) 2009-09-29 US disclosed
US-20090192136-A1 BENZOYL-PIPERAZINE DERIVATIVES ALBERATI-GIANI DANIELA 2009-07-30 US disclosed
US-20090192136-A1 BENZOYL-PIPERAZINE DERIVATIVES ALBERATI-GIANI DANIELA 2009-07-30 US disclosed
US-20090192136-A1 BENZOYL-PIPERAZINE DERIVATIVES ALBERATI-GIANI DANIELA 2009-07-30 US disclosed
US-7485637-B2 Benzoyl-tetrahydropiperidine derivatives HOFFMANN-LA ROCHE INC. (US) 2009-02-03 US disclosed
US-7427612-B2 Benzoyl-piperazine derivatives HOFFMANN-LA ROCHE INC. (US) 2008-09-23 US disclosed
US-7427612-B2 Benzoyl-piperazine derivatives HOFFMANN-LA ROCHE INC. (US) 2008-09-23 US disclosed
CN-101111477-A Benzoyl-tetrahydropyridine as glyt-1 inhibitors HOFFMANN LA ROCHE (CH) 2008-01-23 CN disclosed
EP-1663232-B1 1-(2-AMINO-BENZOYL)-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES HOFFMANN LA ROCHE (CH) 2007-10-03 EP disclosed
EP-1663232-B1 1-(2-AMINO-BENZOYL)-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES HOFFMANN LA ROCHE (CH) 2007-10-03 EP disclosed
CN-1874777-A 1-(2-amino-benzoyl)-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses HOFFMANN LA ROCHE (CH) 2006-12-06 CN disclosed
US-20060148797-A1 Benzoyl-tetrahydropiperidine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2006-07-06 US disclosed
EP-1663232-A1 1-(2-AMINO-BENZOYL)-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES F. HOFFMANN-LA ROCHE AG (CH) 2006-06-07 EP disclosed
US-20050070539-A1 Benzoyl-piperazine derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2005-03-31 US disclosed
WO-2005023260-A1 1- (2-AMINO-BENZOL) -PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES F. HOFFMANN-LA ROCHE AG (CH) 2005-03-17 WO disclosed
WO-2005023260-A1 1- (2-AMINO-BENZOL) -PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES F. HOFFMANN-LA ROCHE AG (CH) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148797-A1 Benzoyl-tetrahydropiperidine derivatives GRIN2A, HTR5A, BACE1 ALDH1A1 143/4885TP53 2387/4885TDP1 1292/4885
US-20050070539-A1 Benzoyl-piperazine derivatives OPRL1, ACHE, PNMT ALDH1A1 582/4885TP53 1334/4885TDP1 335/4885
US-20090192136-A1 BENZOYL-PIPERAZINE DERIVATIVES OPRL1, ACHE, PNMT ALDH1A1 582/4885TP53 1334/4885TDP1 335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.